Abstract: [Objective] To provide a pressure-sensitive adhesive agent for skin containing a pressure-sensitive adhesive agent for skin that has favorable shape retention properties and skin-follow up properties without being adversely affected by moisture from excrement or the like even when adhered to the skin over a long period of time and yet leaves no adhesive residue after separation and a pressure-sensitive adhesive sheet for skin contains a base material and a layer of the pressure-sensitive adhesive agent for skin. [Means to Achieve Objectives] A pressure-sensitive adhesive agent for skin contains 2 to 35% by weight of a thermoplastic elastomer, 25 to 60% by weight of a hydrophilic polymer compound, 16 to 40% by weight of a softener, and 0.01 to 4.8% by weight of a physiologically active agent; and has a water absorption 3 hours after of 55 to 240% and a water absorption 24 hours after of 240 to 450%.

Abstract: The present invention is directed to, for example, an oligosaccharide having at an end thereof a 4-position halogenated galactose residue represented by formula (I): (wherein X represents a halogen atom, and R represents a monosaccharide, an oligosaccharide, or a carrier), a transferase inhibitor containing the oligosaccharide, and a method for inhibiting sugar chain elongation reaction in the presence of glycosyltransferase, the method including employing the inhibitor. The invention also provides a method for producing a 4-position halogenated galactose sugar nucleotide represented by formula (II): (wherein each of R1 to R3 represents a hydroxyl group, an acetyl group, a halogen atom, or a hydrogen atom; X represents a halogen atom; and M represents a hydrogen ion or a metal ion), wherein the method employs bacterium-derived galactokinase and bacterium-derived hexose-1-phosphate uridylyltransferase.

Abstract: A display device and a display panel driving method, in which a matrix panel includes pixel portions each have a series circuit of a bistable element and a light emitting element, every time one scan line is specified in order in accordance with an input image signal, a driving line corresponding to at least one pixel portion to be driven to emit light on the one scan line is specified in accordance with the input image signal, a first predetermined voltage lower than a turn-off threshold voltage is applied between the one scan line and the specified driving line, and thereafter a second predetermined voltage higher than a turn-on threshold voltage is applied therebetween.

Abstract: Cell-free systems which effect the production of polyketides employing modular polyketide synthases are described. Libraries of new and/or known polyketides may also be produced in cell-free systems employing aromatic PKS, modular PKS or both.

Abstract: Transition metal complexes, referred to hereinafter as “metalloligands”, that catalyze the degradation of DNA and the cleavage of RNA at select sites are provided. In one embodiment, the metalloligand has the following structure: wherein R1 is an amino group, i.e. an NH, or an alkylamino group comprising 1 or 2 carbon atoms; wherein R2 is selected from the group consisting of an amino group, a hydroxyl group, i.e., O(H), an alkylamino group comprising 1 or 2 carbon atoms; and an alkylhydroxyl group comprising 1 or 2 carbon atoms; wherein J is a ligand which comprises at least one carbon-containing five-membered or six-membered ring structure; and wherein M is a transition metal ion which is bound via coordinate bonds to R1 and R2.

Abstract: The present invention is directed to a method for cloning and producing the FnuDI restriction endonuclease by (1) introducing the restriction endonuclease gene from F. nucleatum D into a host whereby the restriction gene is expressed; (2) fermenting the host which contains the vector encoding and expressing the FnuDI restriction endonuclease, and (3) purifying the FnuDI restriction endonuclease from the fermented host which contains the vector encoding and expressing the FnuDI restriction endonuclease activity.

Abstract: Boholmycin antibiotic is prepared by fermentation of Streptomyces hygroscopicus H617-25 (ATCC No. 53240) in a nutrient medium preferably comprising glycerol, bacto-liver, cornsteep liquor, ammonium sulfate, sodium chloride and calcium carbonate. The antibiotic and pharmaceutically acceptable salts and hydrates thereof and compositions containing these are effective against Gram-positive, Gram-negative and acid-fast bacteria and against bacterial strains which are resistant to previously known aminoglycoside antibiotics and are useful to treat bacterial infections in mammals.

Abstract: Antibiotic Bu-2659 complex, containing components A, B, C, D and E, is produced by cultivation of Streptomyces hygroscopicus Strain No. J296-21, ATCC No. 39150.

Abstract: Novel antibiotics of the following structure ##STR1## wherein R represents a moiety selected from the group consisting of hydrogen, --COCH.sub.2 NH.sub.2, --COCH.sub.2 NHCONH.sub.2 and --COCH.sub.2 NHCHO;process for preparation thereof; and biologically pure culture for use therein.

Abstract: Novel aminoglycoside-aminocyclitol derivatives corresponding to the general formula: ##STR1## wherein R.sub.1 and R.sub.2, which are different, represent hydrogen or CH.sub.2 NH.sub.2 and R is selected from the group consisting of: ##STR2## wherein R.sub.3 represents NH.sub.2 or OH and R.sub.4 represents ##STR3## wherein R.sub.5 represents hydrogen or methyl and the pharmaceutically acceptable acid addition salts thereof.They are useful as antibiotics.